Developer docs
API playgroundTry for free, no card

Search company profiles

The LEO Foundation

Full company profile

uuid002excg

Namestring
The LEO Foundation
Legal namestring
LEO Foundation
Company typeenum
Private
Founded yearint
1984
Descriptiontext

The LEO Foundation is a Danish enterprise foundation established in 1984 to secure the long-term continuation and development of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology that was itself founded in 1908. It operates as a permanent, ownerless controlling shareholder with no personal beneficiaries, and discharges its purpose through three interconnected activities: (1) engaged ownership of approximately 80% of LEO Pharma (held via wholly-owned LEO Holding A/S, with Nordic Capital as the remaining minority shareholder); (2) philanthropic grant-making, deploying open-competition Research Grants (three annual funding rounds) to independent dermatology research worldwide, with cumulative grants of approximately DKK 1.8 billion since inception; and (3) responsible management of a financial asset portfolio of approximately DKK 18.8 billion (roughly EUR 2.5 billion) spanning liquid assets (listed shares, government and covered bonds, credit) and alternatives (structured credit, private equity, infrastructure, real estate), held through LEO Holding A/S. Its internal technology stack is administrative rather than product-oriented: there is no proprietary technology platform, AI/ML capability, or commercial software product; instead the Foundation runs a structured grant application and scientific evaluation process supported by an international panel of independent experts.

The Foundation serves two distinct constituencies. Its philanthropic beneficiaries are academic researchers and research institutions worldwide working on the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases, reached through the open-competition Research Grants program. Its other constituency is indirect: through its controlling stake in LEO Pharma, it underwrites the development and global distribution of medical dermatology therapies for patients with skin diseases. Revenue is not disclosed at the Foundation level; the Foundation's inflows are investment returns on its DKK 18.8 billion portfolio together with the value created at LEO Pharma, while its outflows are philanthropic grants and the cost of a small Copenhagen-based team of fewer than 20 employees led by CEO Peter Haahr, CSO Anne-Marie Engel, and CIO Morten Stampe Christensen. The Foundation's head office is at Lautrupsgade 7, Copenhagen Ø, Denmark.

Short descriptiontext

The LEO Foundation is a Danish enterprise foundation that permanently owns approximately 80% of LEO Pharma A/S, the global medical dermatology pharmaceutical company, while also serving as one of the world's largest private funders of independent skin research and managing a DKK 18.8 billion investment portfolio. It has no owners or personal beneficiaries and serves academic researchers worldwide through open-competition grants and, indirectly, patients via LEO Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermatology research grants, pharmaceutical ownership, enterprise foundation, skin disease research, philanthropic grant-making
Industry3 codes
PRIMARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
NAICS code2 codes
  • Grantmaking Foundations813211
  • Religious, Grantmaking, Civic, Professional, and Similar Organizations813
SIC code1 code
  • Investors, Nec6799
Product category
Philanthropic Foundation
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Philanthropic Grant-Making
TypeLicensing Royalties
Description

The Foundation provides grants to dermatology and skin disease research. The Foundation does not generate revenue from this activity; rather, it deploys its financial resources to support scientific research.

leo-foundation.org
2Engaged Ownership of LEO Pharma
TypeSubscription Recurring
Description

The Foundation holds approximately 80% controlling ownership of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology. This ownership generates value through the company's operations and strategic development.

leo-foundation.org
3Investment Returns
TypeSubscription Recurring
Description

The Foundation's investment portfolio generates returns to support LEO Pharma's long-term continuation and strategic development, as well as providing a growing basis for philanthropic grants. Financial assets of approximately DKK 18.8 billion (~EUR 2.5 billion) are invested across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

leo-foundation.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The LEO Foundation is a Danish enterprise foundation that operates through three interconnected activities: (1) engaged ownership of LEO Pharma A/S as an approximately 80% controlling shareholder, supporting the global pharmaceutical company's development in medical dermatology; (2) philanthropic Research Grants provided through an open-competition process with three annual funding rounds to support independent skin disease research worldwide; and (3) management of a diversified financial investment portfolio of approximately DKK 18.8 billion through its wholly-owned subsidiary LEO Holding A/S.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • DKK 59 million granted for inflammatory skin disease research
+1 more record
Product overview1 text field

The LEO Foundation operates as a Danish enterprise foundation with three interconnected activities: (1) engaged ownership of LEO Pharma A/S, holding approximately 80% controlling shareholder position in the global pharmaceutical company specializing in medical dermatology; (2) provision of philanthropic Research Grants through an open competition process with three annual funding rounds to support dermatology research worldwide; and (3) management of financial assets of approximately DKK 18.8 billion through its wholly owned subsidiary LEO Holding A/S, which includes liquid assets and alternative investments to generate returns supporting LEO Pharma's development and the Foundation's grant-making activities.

Product and service3 records
1LEO Pharma Ownership
CategoryOwnership / Holding
Description

Engaged ownership stake of approximately 80% controlling share in LEO Pharma A/S, a global pharmaceutical company and leader in medical dermatology founded in 1908, setting standards of care for people with skin conditions.

2Research Grants
CategoryPhilanthropic Grants
Description

Open competition research grants given to support the best dermatology research projects worldwide, with three annual funding rounds evaluating applications for underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases.

3Financial Investments
CategoryInvestment Management
Description

Investment management through wholly-owned subsidiary LEO Holding A/S, managing approximately DKK 18.8 billion in financial assets across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Carlsberg Foundation
TypeDirect peer
Description

Danish enterprise foundation that is the largest shareholder in Carlsberg and a major scientific research funder. Closely analogous enterprise foundation model combining controlling industrial ownership with substantial scientific grantmaking in Denmark.

2Lundbeck Foundation
TypeDirect peer
Description

Danish enterprise foundation controlling H. Lundbeck and one of Denmark's largest research grantmakers, with a focus on neuroscience. Highly comparable to LEO Foundation in Danish enterprise foundation structure, controlling pharma ownership, and grantmaking within a specific therapeutic area.

3Novo Nordisk Foundation
TypeDirect peer
Description

Danish enterprise foundation that is the controlling shareholder of Novo Nordisk and one of the world's largest private funders of scientific research. Closely comparable to LEO Foundation in structure: Danish enterprise foundation with controlling pharma ownership combined with major scientific grantmaking.

TypeBroad incumbent
Description

The world's largest private philanthropic foundation with massive global health and biomedical grantmaking programs. Comparable as a major health-focused research grantmaking foundation, though at much greater scale and broader scope than LEO Foundation.

TypeDirect peer
Description

Danish philanthropic foundations focused on research, sustainability, and social causes. Comparable as Danish research-focused grantmaking foundations with strong scientific orientation and operating in overlapping Danish philanthropic ecosystems with LEO Foundation.

TypeDirect peer
Description

US-based philanthropic foundation focused on health and healthcare. Comparable as a large health-focused foundation with substantial grantmaking activities, though operating in a different national jurisdiction.

7Howard Hughes Medical Institute
TypeDirect peer
Description

US-based medical research organization that is one of the largest private funders of biomedical research globally, supporting scientists across many institutions. Comparable as a major private biomedical research foundation with significant grant deployment.

TypeEmerging player
Description

US-based foundation funding basic scientific research across multiple disciplines including neuroscience and physics. Comparable as a science-focused grantmaking foundation, though with broader scientific scope and US-centric operations rather than dermatology specialization.

TypeDirect peer
Description

UK-based independent charitable foundation that is one of the world's largest funders of biomedical and health research. Comparable as a major privately-endowed research foundation with substantial grant deployment into biomedical science globally.

TypeDirect peer
Description

Danish enterprise foundation that is the controlling shareholder of A.P. Møller-Mærsk and a major supporter of Danish scientific, educational, and humanitarian initiatives. Directly comparable as a Danish enterprise foundation with controlling industrial ownership and significant philanthropic activities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The LEO Foundation

Philanthropic Foundationleo-foundation.org

The LEO Foundation is a Danish enterprise foundation that permanently owns approximately 80% of LEO Pharma A/S, the global medical dermatology pharmaceutical company, while also serving as one of the world's largest private funders of independent skin research and managing a DKK 18.8 billion investment portfolio. It has no owners or personal beneficiaries and serves academic researchers worldwide through open-competition grants and, indirectly, patients via LEO Pharma.

What The LEO Foundation does

The LEO Foundation is a Danish enterprise foundation established in 1984 to secure the long-term continuation and development of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology that was itself founded in 1908. It operates as a permanent, ownerless controlling shareholder with no personal beneficiaries, and discharges its purpose through three interconnected activities: (1) engaged ownership of approximately 80% of LEO Pharma (held via wholly-owned LEO Holding A/S, with Nordic Capital as the remaining minority shareholder); (2) philanthropic grant-making, deploying open-competition Research Grants (three annual funding rounds) to independent dermatology research worldwide, with cumulative grants of approximately DKK 1.8 billion since inception; and (3) responsible management of a financial asset portfolio of approximately DKK 18.8 billion (roughly EUR 2.5 billion) spanning liquid assets (listed shares, government and covered bonds, credit) and alternatives (structured credit, private equity, infrastructure, real estate), held through LEO Holding A/S. Its internal technology stack is administrative rather than product-oriented: there is no proprietary technology platform, AI/ML capability, or commercial software product; instead the Foundation runs a structured grant application and scientific evaluation process supported by an international panel of independent experts.

The Foundation serves two distinct constituencies. Its philanthropic beneficiaries are academic researchers and research institutions worldwide working on the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases, reached through the open-competition Research Grants program. Its other constituency is indirect: through its controlling stake in LEO Pharma, it underwrites the development and global distribution of medical dermatology therapies for patients with skin diseases. Revenue is not disclosed at the Foundation level; the Foundation's inflows are investment returns on its DKK 18.8 billion portfolio together with the value created at LEO Pharma, while its outflows are philanthropic grants and the cost of a small Copenhagen-based team of fewer than 20 employees led by CEO Peter Haahr, CSO Anne-Marie Engel, and CIO Morten Stampe Christensen. The Foundation's head office is at Lautrupsgade 7, Copenhagen Ø, Denmark.

The LEO Foundation firmographics

Firmographics
Name
The LEO Foundation
Legal name
LEO Foundation
Website
https://leo-foundation.org
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
11–50 employees
Short description
The LEO Foundation is a Danish enterprise foundation that permanently owns approximately 80% of LEO Pharma A/S, the global medical dermatology pharmaceutical company, while also serving as one of the world's largest private funders of independent skin research and managing a DKK 18.8 billion investment portfolio. It has no owners or personal beneficiaries and serves academic researchers worldwide through open-competition grants and, indirectly, patients via LEO Pharma.
Ownership category
akta.pro rank

The LEO Foundation industry classification

Industry
Product category
Philanthropic Foundation
NAICS
Grantmaking Foundations (813211), Religious, Grantmaking, Civic, Professional, and Similar Organizations (813)
SIC
Investors, Nec (6799)
akta.pro industry
PRIMARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Keywords

  • Dermatology research grants
  • Pharmaceutical ownership
  • Enterprise foundation
  • Skin disease research
  • Philanthropic grant-making

Where The LEO Foundation is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

The LEO Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Philanthropic Grant-Making: The Foundation provides grants to dermatology and skin disease research. The Foundation does not generate revenue from this activity; rather, it deploys its financial resources to support scientific research.
  2. Engaged Ownership of LEO Pharma: The Foundation holds approximately 80% controlling ownership of LEO Pharma A/S, a global pharmaceutical company specializing in medical dermatology. This ownership generates value through the company's operations and strategic development.
  3. Investment Returns: The Foundation's investment portfolio generates returns to support LEO Pharma's long-term continuation and strategic development, as well as providing a growing basis for philanthropic grants. Financial assets of approximately DKK 18.8 billion (~EUR 2.5 billion) are invested across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

The LEO Foundation product offering

Product offering

Core offering

The LEO Foundation is a Danish enterprise foundation that operates through three interconnected activities: (1) engaged ownership of LEO Pharma A/S as an approximately 80% controlling shareholder, supporting the global pharmaceutical company's development in medical dermatology; (2) philanthropic Research Grants provided through an open-competition process with three annual funding rounds to support independent skin disease research worldwide; and (3) management of a diversified financial investment portfolio of approximately DKK 18.8 billion through its wholly-owned subsidiary LEO Holding A/S.

Product overview

The LEO Foundation operates as a Danish enterprise foundation with three interconnected activities: (1) engaged ownership of LEO Pharma A/S, holding approximately 80% controlling shareholder position in the global pharmaceutical company specializing in medical dermatology; (2) provision of philanthropic Research Grants through an open competition process with three annual funding rounds to support dermatology research worldwide; and (3) management of financial assets of approximately DKK 18.8 billion through its wholly owned subsidiary LEO Holding A/S, which includes liquid assets and alternative investments to generate returns supporting LEO Pharma's development and the Foundation's grant-making activities.

Differentiator

Problem solved

Functional benefit

Products and services

  • LEO Pharma Ownership Engaged ownership stake of approximately 80% controlling share in LEO Pharma A/S, a global pharmaceutical company and leader in medical dermatology founded in 1908, setting standards of care for people with skin conditions.
  • Research Grants Open competition research grants given to support the best dermatology research projects worldwide, with three annual funding rounds evaluating applications for underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases.
  • Financial Investments Investment management through wholly-owned subsidiary LEO Holding A/S, managing approximately DKK 18.8 billion in financial assets across liquid assets (listed shares, government bonds, covered bonds, credit) and alternative investments (structured credit, private equity, infrastructure, real estate).

Quantifiable outcome

  • DKK 59 million granted for inflammatory skin disease research
  • +1 more outcomes

Companies that use The LEO Foundation

Customer profile

Segments2 records

Ideal customer profiles2 records

The LEO Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

The LEO Foundation partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

The LEO Foundation competitors and assessment

Company assessment

Direct peers

  • Carlsberg Foundation: Danish enterprise foundation that is the largest shareholder in Carlsberg and a major scientific research funder. Closely analogous enterprise foundation model combining controlling industrial ownership with substantial scientific grantmaking in Denmark.
  • Lundbeck Foundation: Danish enterprise foundation controlling H. Lundbeck and one of Denmark's largest research grantmakers, with a focus on neuroscience. Highly comparable to LEO Foundation in Danish enterprise foundation structure, controlling pharma ownership, and grantmaking within a specific therapeutic area.
  • Novo Nordisk Foundation: Danish enterprise foundation that is the controlling shareholder of Novo Nordisk and one of the world's largest private funders of scientific research. Closely comparable to LEO Foundation in structure: Danish enterprise foundation with controlling pharma ownership combined with major scientific grantmaking.
  • Velux Foundations: Danish philanthropic foundations focused on research, sustainability, and social causes. Comparable as Danish research-focused grantmaking foundations with strong scientific orientation and operating in overlapping Danish philanthropic ecosystems with LEO Foundation.
  • Robert Wood Johnson Foundation: US-based philanthropic foundation focused on health and healthcare. Comparable as a large health-focused foundation with substantial grantmaking activities, though operating in a different national jurisdiction.
  • Howard Hughes Medical Institute: US-based medical research organization that is one of the largest private funders of biomedical research globally, supporting scientists across many institutions. Comparable as a major private biomedical research foundation with significant grant deployment.
  • Wellcome Trust: UK-based independent charitable foundation that is one of the world's largest funders of biomedical and health research. Comparable as a major privately-endowed research foundation with substantial grant deployment into biomedical science globally.
  • A.P. Møller Foundation: Danish enterprise foundation that is the controlling shareholder of A.P. Møller-Mærsk and a major supporter of Danish scientific, educational, and humanitarian initiatives. Directly comparable as a Danish enterprise foundation with controlling industrial ownership and significant philanthropic activities.

Broad incumbents

  • Bill & Melinda Gates Foundation: The world's largest private philanthropic foundation with massive global health and biomedical grantmaking programs. Comparable as a major health-focused research grantmaking foundation, though at much greater scale and broader scope than LEO Foundation.

Emerging players

  • Kavli Foundation: US-based foundation funding basic scientific research across multiple disciplines including neuroscience and physics. Comparable as a science-focused grantmaking foundation, though with broader scientific scope and US-centric operations rather than dermatology specialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

The LEO Foundation social profiles

Digital presence

The LEO Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The LEO Foundation leadership team

Management profile

Number of profiles

Profiles16 records

The LEO Foundation subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

The LEO Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The LEO Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The LEO Foundation

What does The LEO Foundation do?

The LEO Foundation is a Danish enterprise foundation that operates through three interconnected activities: (1) engaged ownership of LEO Pharma A/S as an approximately 80% controlling shareholder, supporting the global pharmaceutical company's development in medical dermatology; (2) philanthropic Research Grants provided through an open-competition process with three annual funding rounds to support independent skin disease research worldwide; and (3) management of a diversified financial investment portfolio of approximately DKK 18.8 billion through its wholly-owned subsidiary LEO Holding A/S.

Is The LEO Foundation a public or private company?

The LEO Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The LEO Foundation founded?

The LEO Foundation was founded in 1984. It employs 11 to 50 people.

Where is The LEO Foundation based?

The LEO Foundation is headquartered in Copenhagen, Denmark, in the Europe region.

How does The LEO Foundation make money?

Three revenue lines are on record. Philanthropic Grant-Making is the primary driver. The others are engaged Ownership of LEO Pharma and investment Returns.

Who are The LEO Foundation's main competitors?

Direct peers on record are Carlsberg Foundation, Lundbeck Foundation, Novo Nordisk Foundation, Velux Foundations, Robert Wood Johnson Foundation, Howard Hughes Medical Institute, Wellcome Trust and A.P. Møller Foundation. Bill & Melinda Gates Foundation is listed as a broad incumbent. Kavli Foundation is listed as an emerging player.

Does The LEO Foundation have an API?

No public API is recorded for The LEO Foundation.

What industry is The LEO Foundation in?

The LEO Foundation's product category is Philanthropic Foundation. Its primary akta.pro industry code is BPAGAKAA, Private Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals